

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED

TidalHealth Nanticoke, Inc.
801 Middleford Road
Seaford, DE 19973

2. NRC/REGIONAL OFFICE

Region 1
475 Allendale Rd
Suite 102
King of Prussia, PA 19406

REPORT NUMBER(S) 2025001

3. DOCKET NUMBER(S)

030-13060

4. LICENSE NUMBER(S)

07-17618-01

5. DATE(S) OF INSPECTION

04/07/2025 - 05/28/2025

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- ☐ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

- ☒ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with the NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)

10 CFR 35.63(d) requires unless otherwise directed by the authorized user, a licensee may not use a dosage if the dosage does not fall within the prescribed dosage range or if the dosage differs from the prescribed dosage by more than 20 percent.


Contrary to the above, the licensee was not directed by the authorized user to use a dosage that does not fall within the prescribed dosage range or differed from the prescribed dosage by more than 20 percent. Specifically, in February 2024, five administrations were found to be greater than a 20 percent difference.

This is a Severity Level IV violation per the NRC Enforcement Policy (Section 6.3.d).

For corrective actions, the licensee will implement a yearly review of the prescribed dose schedule with a health physicist and RSO to current and new employees. The licensee has updated their procedures to be explicit in getting Authorized User approval for a dose that is outside of the prescribed range or more than 20% difference of the prescribed dosage. This includes a document with the AU approval being part of the patient chart.

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE	Charles Dolan		04/11/25
NRC INSPECTOR	Kelli Trotter		
BRANCH CHIEF	Monica Ford		